Compositions and methods for inhibiting dihydroorotate dehydrogenase

Inventors

Kumar, Vikram S. • Hesson, David P. • Huang, Ping • Jia, Mo • You, Xianjun

Assignees

Clear Creek Bio Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10889548-B2

Patent

Publication Date

2021-01-12

Expiration Date


Abstract

The invention provides therapeutic compositions that contain an inhibitor of dihydroorotate dehydrogenase (DHODH) and promote sustained elevation of dihydroorotate (DHO) levels in a patient. The compositions are useful for treating disorders associated with unregulated DHODH activity, such as acute myeloid leukemia. The invention also provides methods of determining therapeutically effective doses of compositions that contain a DHODH inhibitor. The invention further provides methods of synthesis of 2-(2′-halo-1-1′-biphenyl-4-yl)-quinoline carboxylic acids, which are useful as DHODH inhibitors.

Core Innovation

The patent describes a method of making a 2-(2′-halo-1-1′-biphenyl-4-yl)-quinoline carboxylic acid. The method includes incubating a compound of formula (I) with a compound of formula (II) in a mixture comprising a base, at 60° C. to 70° C. for 15 hours to 30 hours.

After the incubation, an acid is added to the mixture to create a compound of formula (III). The reaction is defined such that R1, R2, R3, and R4 are independently H, F, Cl, Br, I, CH3, CF3, SCH3, or CH2CH3, with at least two of R1, R2, R3, and R4 being H; R5 is H, an alkoxy of 1-3 carbon atoms, or an alkyl of 1-2 carbon atoms; R6 and R7 are independently H, F, Cl, Br, alkyl of 1-5 carbon atoms, NO2, OH, CF3, or OCH3; and X is a halogen.

The disclosed approach includes dependent claims and examples that further refine the incubation mixture conditions, product performance outcomes, and specific reagent selections. The claims also include a target-engagement dosing strategy for DHODH-targeting therapy using DHODH inhibitors while maintaining a therapeutic window through dosing based on measured DHO.

Claims Coverage

Independent claim coverage is present for making the specified 2-(2′-halo-1-1′-biphenyl-4-yl)-quinoline carboxylic acid, with dependent claims refining the incubation mixture conditions, performance outcome, and specific reagent selections. Across the claims shown, multiple inventive features are specified as quantitative constraints, structural limitations, and reagent selections.

Incubating compound of formula (I) with compound of formula (II) in a base-containing mixture

Incubating a compound of formula (I) with a compound of formula (II) in a mixture comprising a base at a temperature of from 60° C. to 70° C. for from 15 hours to 30 hours.

Adding an acid to create a compound of formula (III)

Adding an acid to the mixture, thereby creating a compound of formula (III) according to the defined reaction.

Base-to-compound molar ratio of about 5:1 to about 8:1

The incubating step includes a mixture having a molar ratio of the base to the compound of formula (II) in the range of about 5:1 to about 8:1.

Minimum yield of at least 80%

Producing a compound of formula (III) with a yield of at least 80%.

Base selected from KOH, NaOH, or NH4OH

Specifying that the base is chosen from KOH, NaOH, or NH4OH.

Acid selected from HCl and acetic acid

Specifying that the acid used is selected from HCl and acetic acid.

Product structure represented by formula (IV)

Carrying out such that the compound of formula (III) has the chemical structure shown by formula (IV).

The claims focus on a defined making method for the specified 2-(2′-halo-1-1′-biphenyl-4-yl)-quinoline carboxylic acid, combining a base-containing incubation with subsequent acid addition to form a compound of formula (III). Dependent claim features further narrow the approach via a specific base-to-compound molar ratio range, a minimum yield threshold, selected base and acid reagents, and a required product structure representation via formula (IV).

Stated Advantages

Not explicitly described in patent.

Documented Applications

Not explicitly described in patent.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.